Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience.
Metastatic renal cell carcinoma
SBRT
Stereotactic ablative radiotherapy
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
09
03
2022
accepted:
06
04
2022
pubmed:
24
6
2022
medline:
31
8
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6-7.5, p = 0.0012 and HR 2.8, 95% CI 0.99-8.07, p = 0.05, respectively). Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.
Identifiants
pubmed: 35739349
doi: 10.1007/s12094-022-02844-5
pii: 10.1007/s12094-022-02844-5
pmc: PMC9418086
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2039-2043Informations de copyright
© 2022. The Author(s).
Références
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–85.
doi: 10.1016/S1470-2045(19)30413-9
Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–73.
doi: 10.1016/S1470-2045(20)30436-8
Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300.
doi: 10.1056/NEJMoa2035716
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
doi: 10.1056/NEJMoa1510665
Ljungberg B, Albiges L, Bedke J, et al. EAU guidelines on renal cell carcinoma. 2021 edition. Available at: https://uroweb.org/guideline/renal-cell-carcinoma/ .
Masini C, Iotti C, De Giorgi U, et al. Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): first results of phase II NIVES study. J Clin Oncol. 2020;38(6):613–613.
doi: 10.1200/JCO.2020.38.6_suppl.613
Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18(4):240–3.
doi: 10.1016/j.semradonc.2008.04.005
Hammers HJ, Vonmerveldt D, Ahn C, et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). J Clin Oncol. 2020;38(6):614–614.
doi: 10.1200/JCO.2020.38.6_suppl.614
Siva S, Bressel M, Wood S, et al. Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: the RAPPORT trial. J Clin Oncol. 2021;39(6):277–277.
doi: 10.1200/JCO.2021.39.6_suppl.277